Simple Chemoinformatics Criterion for Selection of Antibiotics Against MDR Bacteria
DISCOVERIES (ISSN 2359-7232), 2016, July-September issue
Submitted: September 23, 2016; Revised: September 28, 2016; Accepted: September 28, 2016; Published: October 1, 2016;
GO BACK to 2016, July-September issue
GO BACK to DISCOVERIES
Simple Chemoinformatics Criterion Using Electron Donor-Acceptor Molecular Characteristics for Selection of Antibiotics Against Multi-Drug-Resistant Bacteria
Veljko Veljkovic (1,2), Sanja Glisic (2), Vladimir Perovic (2), Slobodan Paessler (3), Nevena Veljkovic (2), Garth L Nicolson (4,*)
(1) Biomed Protection, Galveston, TX, USA
(2) Center for Multidisciplinary Research, University of Belgrade, Institute of Nuclear Sciences VINCA, P.O. Box 522, 11001 Belgrade, Serbia
(3) Department of Pathology, Galveston National Laboratory, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX, USA
(4) Department of Molecular Pathology, The Institute for Molecular Medicine, Huntington Beach, CA, USA
*Correspondence to: Garth L Nicolson, PhD, MD (H), Department of Molecular Pathology, The Institute for Molecular Medicine, Huntington Beach, CA, 92647, USA; Email: gnicolson@immed.org; Fax: 714-596-3791
Abstract
Recent outbreaks of NDM-1-positive Entero-bacteriaceae in Great Britain and India and the highly pathogenic Escherichia coli strain EHEC O104:H4 in Germany and some other E.U. countries point out an urgent need for the ability to decide on appropriate antibiotics to treat multi-drug-resistant (MDR) bacteria. Here we propose a simple criterion for choosing antibiotics based on characteristics of electron donor and acceptor properties. Using molecular descriptors, such as electron-ion interaction potential (EIIP) and average quasi-valence number (AQVN), which can describe potential long-range interactions between therapeutic molecules and their targets, we have been able to suggest appropriate antibiotics for treatment of MDR bacterial infections. To demonstrate the prospective usefulness of these molecular descriptors we have used this informatics system to propose that pleuromutilins and nitrofurans could be effective against of NDM-1-positive Enterobacteriacea and that aminoglycosides, macrolides and pluromutilins (and possibly nitrofurans) could be suitable for treatment of the highly pathogenic Escherichia coli strain EHEC O104:H4. Similarly, because of their specific electronic properties, we can also suggest antibiotics that could be potentially effective against other MDR bacteria. The proposed antibiotics should be further evaluated for their treatment potentials.
Access full text of the manuscript here: Full text (pdf) Suppl. Material (pdf)
References
1. World Health Organization. World Health Statistics, 2015; Part II, 40-160.
2. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan and the UK: a molecular, biological and epidemiological study. Lancet Infect. Dis. 2010; 10(9): 597-602.
3. http://www.rki.de/cln_178/nn_217400/EN/Home/ EHEC__O104__H4
4. Veljkovic V, Veljkovic N, Esté JA, Hüther A, Dietrich U. Application of the EIIP/ISM bioinformatics concept in development of new drugs. Curr. Med. Chem. 2007; 14(4): 441-453.
5. Todeschini R, Consoni V. Molecular descriptors for chemoinformatics. Wiley VCH Verlag: Weinheim, 2009.
6. Tintori C, Manetti F, Veljkovic N, Perovic V, Vercammen J, Hayes S et al. Novel virtual screening protocol based on the combined use of molecular modeling and electron-ion interaction potential techniques to design HIV-1 integrase inhibitors. J. Chem. Infect. Model. 2007; 47: 1536-1544.
7. Mugnaini C, Rajamaki S, Tintori C, Corelli F, Massa S, Witvrouw M et al. Toward novel HIV-1 integrase binding inhibitors: molecular modeling, synthesis, and biological studies. Bioorganic Med. Chem. Lett. 2007; 17: 5370-5373.
8. Veljkovic V, Mouscadet JF, Veljkovic N, Glisic S, Debyser Z. Bioorganic Med. Chem. Lett. 2007; 17: 1226-1232.
9. Veljkovic V. A theoretical approach to preselection of carcinogens and chemical carcinogenesis. Gordon & Breach: New York, 1980.
10. Veljkovic V, Slavic I. Simple general-model pseudopotential. Phys. Rev. Lett. 1972; 29: 105-107.
11. Veljkovic V. The dependence of the Fermi energy on the atomic number. Phys. Lett. 1973; 45A: 41-42.
12. Theuretzbacher U. Future antibiotics scenarios: is the tide starting to turn? Int. J. Antimicrob Agents 2009; 34: 15-20.
News & Events Latest news from Discoveries
- 2022, April| AWARDS!
2022 Discoveries Award winning articles!
- Kinal Bhatt et al. 2021 (Larking Health System, FL, USA); Bhatt K, Agolli A, Patel MH, et al. High mortality co-infections of COVID-19 patients: mucormycosis and other fungal infections. Discoveries. 2021;9(1):e126.
27 citations in the past 1 year - $1000 prize- Hasnain Jan et al. 2020 (Quaid-i-Azam University, Pakistan); Jan H, Faisal S, Khan A, et al. COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus. Discoveries. 2020;8(2):e108.
23 citations in the past 2 years - $400 prizeCongratulations! Prizes will be received by the awardees in July 2022!
- 2021, July| 2021, Jul-September
Due to the high volume of the submitted articles, both Discoveries and Discoveries Reports are experiencing processing and publication delays during the months of July-September 2021. We will get back to the normal processing and publication times starting in October 2021. Note that our editorial and administrativ work is fully funded by our publishing house at this time and we are striving to KEEP THE NO FEE/NO CHARGE strategy in place as long as possible.
- 2021, January| AWARDS!
2022 DISCOVERIES AWARDS! Discoveries will offer $1000 and $400 awards in early 2022, for the most cited (2021 ISI Citations) and visible articles published in 2018-2021.
- 2020, November| Follow us on Twitter!
You can now follow the latest Discoveries news and updates on Twitter! (@DiscoveriesNews)
- 2020, August| For Authors!
Due to a high volume of article submissions, our peer-review process takes more than usual. The pre-screening decision is released in 1-2 days, while the peer-review process lasts between 10 and 20 days.
- 2020, April | For Authors!
WE DO NOT TOLERATE ANY MISCONDUCT! Please be aware that we are testing all received articles with specialized software for PLAGIARISM and WE WILL TAKE MEASURES if your article is already published or in consideration for publication by other journals! This may result in serious professional consequences for the authors. The latest striking case is the following article which is already published and was re-submitted here.
- 2020, April | For Authors!
We are happy to let you know that all articles published in Discoveries are now included in PubMedCentral (PMC). New accepted articles will be included in PMC and PubMed within 1-2 weeks after their publication.
- 2020, January | For Authors!
Starting in January 2020, Discoveries will also consider articles submitted by Discoveries' Editorial Board members. However, only a small number of such articles (maximum 4 articles/year) will be considered for publication after the peer-review process, and the authors who are also our editors will be clearly disclosed on our website.
- 2019, September | Indexed by PMC
Discoveries is now indexed by PubMedCentral and Pubmed. The agreement with US National Library of Medicine was signed on September 10, 2019. Our next step is ISI Web of Science indexing. NOTE: previously published articles will be included on PubMed in early 2020.
- 2019, September | PubMed inclusion!
We are happy to let you know that Discoveries successfuly passed the last step (Technical Review) required for PubMedCentral and PubMed inclusion!
- 2019, July | PubMed inclusion News!
We are happy to receive positive comments from PMC/NLM-NIH regarding Discoveries' last step (Technical Review) required for PubMedCentral and PubMed inclusion. We will let you know once whole indexing process is completed.
- 2019| Sharing and Distribution!
All articles published in Discoveries are Open Access articles distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited and it is not used for commercial purposes.
- 2018-2019 | For Authors!
From now on and for at least 1 year, we will only accept articles from authors that are NOT members of Discoveries' Editorial Board. All articles submitted by our editors will be immediately rejected until further notice (one accepted article was already rejected).
- 2018 | PubMed inclusion News!
Discoveries successfully passed the Scientific Quality Review by NLM-NIH for PubMedCentral and PubMed indexing. This is the first and the most important step towards PubMedCentral and PubMed indexing! The second (last) step is the Technical Review.
- 2016, April | Faster Peer-Review
Starting on April 13th 2016, all articles selected for a peer-review will receive the post peer-review decision within ~10 days. The initial pre-screening time will remain the same (48h from the submission of the manuscript). This decision will significantly accelerate the publication, with no effect on the quality of the peer-review process.
- 2016, February | Manuscript submission
Discoveries is commited to excellence, quality and high editorial standards. We are receiving an increasing number of manuscripts for which the identity of the authors/corresponding author can't be verified. Please NOTE that ALL these articles were and will be immediately REJECTED. Indicating an institutional email address is the easiest way to overcome this problem! Moreover, we do not accept any pressure on our editorial board to accept a manuscript. This results in a prompt rejection of the article.
Editorial Policies - 2016, January | Main Objective
After reaching all proposed milestones until now (including being indexed by Google Scholar in 2014), Discoveries' next Aim is PubMed indexing of all its articles (already published and upcoming). There will be no charge for the submission or publication of articles before Discoveries is indexed.
- 2015, August | Discoveries - on PubMed
We are happy to announce that our first Discoveries articles were included in PMC and PubMed. More articles (submitted by NIH funded authors) are now processed for being included.
Discoveries articles now on PubMed - 2015, April | Special Issue
DISCOVERIES published the SPECIAL ISSUE entitled "INFLAMMATION BETWEEN DEFENSE AND DISEASE: Impact on Tissue Repair and Chronic Sickness".
Special Issue on "Inflammation" - 2015 | Ischemia Collection
DISCOVERIES launched a call for papers for a Collection of Articles with focus on "ISCHEMIA". If you are interested to submit a manuscript, please contact us at info@discoveriesjournals.org
- 2014, September | Special Issue
DISCOVERIES just publish the SPECIAL ISSUE entitled "CELL SECRETION & MEMBRANE FUSION" in September 2014. Initially scheduled for publication between October 2014-March 2015, this issue was successfully published earlier than scheduled.
Special Issue - 2014, April | Indexed by Google Scholar
All our published articles are now indexed by Google Scholar! First citations to Discoveries articles are included! Search for the article's title (recommended) or the authors:
Google Scholar Search - 2014 | DISCOVERIES
DOIs (Digital Object Identifiers) are now assigned to all our published manuscripts in Discoveries. DOI uniquely identifies an article and is provided by CrossRef.
CrossRef - 2013, July | Manuscript Submission
Submit your manuscript FREE, FAST and EASY ! (in less than 1 minute)! There are NO fees for the manuscript submission or publishing of the accepted manuscripts.
read more - 2013, July | DISCOVERIES
We are now ACCEPTING MANUSCRIPTS for publishing in DISCOVERIES. We aim publishing a small number of high impact experimental articles & reviews (around 40/year) to maintain a high impact factor. Domains of interest: all areas related to Medicine, Biology and Chemistry ...
read more